MCET +50% has a $1.4M market cap and is trading at $0.01. According to the company’s website, their MCT-465 drug candidate is a Toll-like Receptor (TLR) agonist, and is indicated as prospective therapy for treatment of virus infections including influenza A H1N1 and the “avian flu” virus.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.